can you take semaglutide to lose 10 pounds Semaglutide: Shedding pounds, weighing risks The Pros and Cons of

The clinical implication is not substitution but combination: aggressive ApoB lowering to address the lipid driver of atherogenesis, paired with incretin therapy to address residual cardiometabolic and inflammatory risk

The label recommends blood-sugar monitoring before and during use

Boehringer Ingelheim, in collaboration with Zealand Pharma, will likely be the next big challenger after advancing its promising candidate survodutide, a GCGR/GLP-1R dual agonist, to Phase 3 clinical trials last year

Watch volume trends, GLP 1 market share in key countries, and any guidance updates on margins as management responds to lower price points